Browse for free
← Back to deals
● LiveAcquire· eCommerce· weight loss treatment, online pharmacy

UK Online Pharmacy & Prescribing Platform Specialising in GLP1 Weight Loss Treatments

First seen Sep 5, 2026 · last checked 16 hours ago

Open at Acquire ↗
Asking price
$1,500,000
Annual profit
$182,346
Annual revenue
$2,951,006
Profit multiple
8.20x
Monthly profit
$15,196
Age
1 yr

Confidence in this listing

Enough to judge the shape of it, not enough to price it.

58/100

What is documented
  • Profit figure published
  • Net margin 6%
  • Tracked here for 1 month(s)
What to ask about
  • Listed through a marketplace, figures as supplied
  • A 8.2x multiple, outside what this market clears

This scores the paperwork, not the business. Acquire: listed through a marketplace, figures as supplied. Always verify the figures with the seller before making an offer.

Overview

A fully regulated UK online pharmacy specialising in medical weight loss treatments. The business supports an end-to-end process from online patient consultation to delivery of medication. The business has been established 12 months and has generated approximately £2.2 million in revenue, scaling rapidly from £13.3K in month 1 to approximately £338K in month 12. The valuation is based on the company's current annual revenue run rate of approximately £3.6m and annualised maintainable profit of approximately £270k. Given the significant growth achieved over the past 12 months, the asking price is based on a 4× multiple of maintainable profit at the current annualised run rate, rather than trailing twelve-month performance, which does not accurately reflect the business's current scale and earnings profile. 10,000 registered patients, around 1,700 monthly orders, with strong repeat-customer base. The business has not utilised paid advertising or social media marketing to date. The founder previously exited Bolt Pharmacy when the business was generating around £2 million in revenue. Following the sale, Bolt reportedly grew to an annualised revenue run rate of approximately £450 million within just 16 months whilst being profitable, demonstrating the scale that can potentially be achieved in this sector with the right strategic partner. At Cuva’s current stage of development, the founder believes there remains significant scope to scale the business substantially under the ownership of the right strategic acquirer, particularly one with the expertise and resources to accelerate growth. The medical weight-management market continues to have a very strong growth outlook, with further treatments expected to expand the opportunity. This includes retatrutide, one of the most anticipated weight-loss treatments expected 2026/2027. The founder is open to remaining actively involved in Cuva, potentially for the longer term.

Price & status history

  1. ListedSep 5, 2026

Similar live deals